Literature DB >> 23499630

Prevalence, characteristics, and prognosis role of type 1 ST elevation in the peripheral ECG leads in patients with Brugada syndrome.

A Rollin1, F Sacher, J B Gourraud, J L Pasquié, F Raczka, A Duparc, P Mondoly, C Cardin, M Delay, S Chatel, N Derval, A Denis, M Sadron, J M Davy, M Hocini, P Jaïs, L Jesel, M Haïssaguerre, V Probst, P Maury.   

Abstract

BACKGROUND: Despite isolated reports of Brugada syndrome (BrS) in the inferior or lateral leads, the prevalence and prognostic value of ST elevation in the peripheral electrocardiographic (ECG) leads in patients with BrS remain poorly known.
OBJECTIVE: To study the prevalence, characteristics, and prognostic value of type 1 ST elevation and ST depression in the peripheral ECG leads in a large cohort of patients with BrS.
METHODS: ECGs from 323 patients with BrS (age 47 ± 13 years; 257 men) with spontaneous (n = 141) or drug-induced (n = 182) type 1 ECG were retrospectively reviewed. Two hundred twenty-five (70%) patients were asymptomatic, 72 (22%) patients presented with unexplained syncope, and 26 (8%) patients presented with sudden death (12 patients) or appropriated implantable cardioverter-defibrillator therapies (14 patients) at diagnosis or over a mean follow-up of 48 ± 34 months.
RESULTS: Thirty (9%) patients presented with type 1 ST elevation in at least 1 peripheral lead (22 patients in the aVR leads, 2 in the inferior leads, 5 in both aVR and inferior leads, and 1 in the aVR and VL leads). Patients with type 1 ST elevation in the peripheral leads more often had mutations in the SCN5A gene, were more often inducible, had slower heart rate, and higher J-wave amplitude in the right precordial leads. Twenty-seven percent (8 of 30) of the patients with type 1 ST elevation in the peripheral leads experimented sudden death/appropriate implantable cardioverter-defibrillator therapy, whereas it occurred in only 6% (18 of 293) of other patients (P < .0001). In multivariate analysis, type 1 ECG in the peripheral leads was independently associated with malignant arrhythmic events (odds ratio 4.58; 95% confidence interval 1.7-12.32; P = .0025).
CONCLUSIONS: Type 1 ST elevation in the peripheral ECG leads can be seen in 10% of the patients with BrS and is an independent predictor for a malignant arrhythmic event.
Copyright © 2013 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23499630     DOI: 10.1016/j.hrthm.2013.03.001

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  12 in total

Review 1.  J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge.

Authors:  Charles Antzelevitch; Gan-Xin Yan; Michael J Ackerman; Martin Borggrefe; Domenico Corrado; Jihong Guo; Ihor Gussak; Can Hasdemir; Minoru Horie; Heikki Huikuri; Changsheng Ma; Hiroshi Morita; Gi-Byoung Nam; Frederic Sacher; Wataru Shimizu; Sami Viskin; Arthur A M Wilde
Journal:  Europace       Date:  2017-04-01       Impact factor: 5.214

Review 2.  J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge.

Authors:  Charles Antzelevitch; Gan-Xin Yan; Michael J Ackerman; Martin Borggrefe; Domenico Corrado; Jihong Guo; Ihor Gussak; Can Hasdemir; Minoru Horie; Heikki Huikuri; Changsheng Ma; Hiroshi Morita; Gi-Byoung Nam; Frederic Sacher; Wataru Shimizu; Sami Viskin; Arthur A M Wilde
Journal:  Heart Rhythm       Date:  2016-07-13       Impact factor: 6.343

Review 3.  The Brugada Syndrome - Diagnosis, Clinical Implications and Risk Stratification.

Authors:  Velislav N Batchvarov
Journal:  Eur Cardiol       Date:  2014-12

4.  Novel Therapeutic Strategies for the Management of Ventricular Arrhythmias Associated with the Brugada Syndrome.

Authors:  Bence Patocskai; Charles Antzelevitch
Journal:  Expert Opin Orphan Drugs       Date:  2015-05-13       Impact factor: 0.694

5.  ST Segment Depression in the Inferior Leads in Brugada Pattern: A New Sign.

Authors:  Pasquale Crea; Giuseppe Picciolo; Francesco Luzza; Giuseppe Oreto
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-12-24       Impact factor: 1.468

Review 6.  Risk stratification and treatment of brugada syndrome.

Authors:  Elena Arbelo; Josep Brugada
Journal:  Curr Cardiol Rep       Date:  2014-07       Impact factor: 2.931

Review 7.  Risk Stratification in Brugada Syndrome: Current Status and Emerging Approaches.

Authors:  Shohreh Honarbakhsh; Rui Providencia; Pier D Lambiase
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-06

8.  J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge.

Authors:  Charles Antzelevitch; Gan-Xin Yan; Michael J Ackerman; Martin Borggrefe; Domenico Corrado; Jihong Guo; Ihor Gussak; Can Hasdemir; Minoru Horie; Heikki Huikuri; Changsheng Ma; Hiroshi Morita; Gi-Byoung Nam; Frederic Sacher; Wataru Shimizu; Sami Viskin; Arthur A M Wilde
Journal:  J Arrhythm       Date:  2016-08-21

Review 9.  Risk factors for cardiac events in patients with Brugada syndrome: A PRISMA-compliant meta-analysis and systematic review.

Authors:  Wenqing Wu; Li Tian; Jinshan Ke; Yi Sun; Ruixia Wu; Jianfang Zhu; Qinmei Ke
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

10.  Evaluation of baseline ECG in patients undergoing Oral Flecainide Challenge test for suspected Brugada Syndrome: An analysis of lead II.

Authors:  Maneesh K Rai; Mukund A Prabhu; Jayaprakash Shenthar; Natarajan Kumaraswamy U; Ritesh Vekariya; Padmanabh Kamath; Narasimha Pai; Ramanath L Kamath; Vivek Pillai
Journal:  Indian Pacing Electrophysiol J       Date:  2017-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.